Dual PET/CT Imaging in Lung Cancer

Dual PET/CT Imaging in Lung Cancer (Danish Title: En og Tre Timers FDG-PET/CT Ved Lungecancer)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01539928

Acronym

DILUCE

Enrollment

216

Registered

2012-02-28

Start date

2012-03-31

Completion date

2015-03-31

Last updated

2013-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Dual time PET/CT, glucose-6-phosphatase

Brief summary

The purpose of this study is to compare conventional PET/CT scan performed 1 hour after injection of the radioactive tracer FDG (PET/CT\[1\]) with PET/CT performed after 3 hours (PET/CT\[3\]) in a group of patients with biopsy verified lung cancer or high suspicion of lung cancer after initial work-up (chest x-ray and CT of thorax/upper abdomen), who are potentially operable.

Detailed description

The investigators also want to: * To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up (se Gold Standard 6.1.1) * To compare SUVmax with the expression of GLUT1 and G-6-Pase in tumors * To compare the expression of GLUT1 with the activity of G6Pase * To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of relapse within a year after curative surgery

Interventions

OTHERDual FDG-PET/CT

Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cytologic/histologic-verified lung cancer or high suspicion of lung cancer after initial work up * Candidate to curative intended surgery after initial work up (usually chest x-ray, CT of chest/upper abdomen and if needed spirometry).

Exclusion criteria

* Former lung cancer * Contraindications for PET/CT: Pregnancy, recent chemoradiotherapy * Diabetes mellitus.

Design outcomes

Primary

Measure	Time frame	Description
Sensitivity, specificity and accuracy	After staging or 1 year of follow up	To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up

Secondary

Measure	Time frame	Description
Occurence of relapse	1 year follow up after surgery	• To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of relapse within a year after curative surgery

Countries

Denmark

Contacts

Primary ContactMie H Vilstrup, MD, Principal investigor

mie.holm.vilstrup@rsyd.dk+45 2159 3008

Backup ContactPoul Flemming Høilund-Carlsen, MD, DMSc, Professor

pfhc@rsyd.dk+45 3016 1445

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026